Shopping Cart
Remove All
Your shopping cart is currently empty
Avelumab
Catalog No. T9903 Copy Product Info
Purity: 95%
🥰Excellent
Avelumab, a fully human IgG1 anti-PD-L1 monoclonal antibody, exhibits potential antibody-dependent cell-mediated cytotoxicity.
Avelumab
Copy Product Info🥰Excellent
Catalog No. T9903
Avelumab, a fully human IgG1 anti-PD-L1 monoclonal antibody, exhibits potential antibody-dependent cell-mediated cytotoxicity.
Cas No. 1537032-82-8
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $289 | In Stock | In Stock | |
| 5 mg | $696 | In Stock | In Stock | |
| 10 mg | $987 | - | In Stock | |
| 25 mg | $1,460 | - | In Stock | |
| 50 mg | $1,970 | - | In Stock | |
| 100 mg | $2,660 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:97.17% (SDS-PAGE)
Appearance:Liquid
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Avelumab, a fully human IgG1 anti-PD-L1 monoclonal antibody, exhibits potential antibody-dependent cell-mediated cytotoxicity. |
| Animal Research | Female C57BL/6 mice are used in this study. Subcutaneous tumor injections are carried out by inoculating C57BL/6 mice with 1×105 MB49 parental cells on the right shaved flank. Tumor growth is measured with calipers and 8 days post-inoculation mice are assigned to treatment groups. Tumor-bearing mice are treated with Avelumab (400 μg per 100 μL) and injected i.p. three times, 3 days apart. Since Avelumab is a human IgG1, three injections have to be compressed within a 7 to 9 day window (i.e., days 9, 12, and 15 post-tumor inoculation) to avoid the onset of neutralizing mouse anti-human Ig[3]. |
| Reactivity | Human |
| Verified Activity | Immobilized Human PD-L1 Protein (His) (TMPY-04343) at 1 μg/mL (100 μL/well) can bind Avelumab. The EC50 is 1.730 ng/mL.  |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | B7-H1/PD-L1/CD274 |
| Molecular Weight | 143.8 kDa |
| Cas No. | 1537032-82-8 |
| Relative Density. | no data available |
| Isotype | IgG1 |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Preview
Related Tags: buy Avelumab | purchase Avelumab | Avelumab cost | order Avelumab | Avelumab chemical structure | Avelumab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.